EOS Capital takes 35% stake in Fabupharm

Eos Capital, the Namibian private equity firm founded by Johannes !Gawaxab , is acquiring a 35% in Fabupharm, a pharmaceutical manufacturer with regional expansion ambitions. Financial terms of the deal, which is subject to regulatory approval by the country’s Competition Commission, were not disclosed.

Fabupharm, which operates the only pharmaceutical manufacturing plant in Namibia, produces a range of products including paracetamol, antibiotics, vitamin supplements and sunscreen. Established in 1989 and located in Otjiwarongo, the company employs more than 70 employees and counts Central Medical Stores which supply the Namibian Government’s hospitals and clinics, and several local retailers and pharmacists among its clients. The firm has also secured export approval for a number of its products to be shipped to Botswana, Mozambique and Lesotho and a number of other countries.

To read this article, you must be a paid subscription member. (Current members login here)


Reserve your digital subscription today

Join now for $35 per month

Join now for $395 per year

for access to:

  • Weekly newsletter with original and curated news, analysis and perspective
  • Africa’s private capital deals, fund raises and the investment firms and executives involved
  • Portfolio company news that impacts value and stakeholder participation
  • Job moves and partnerships between leading market participants
  • Exclusive access to Africa Capital Digest’s full content archive

If you’d like more information on exceptional value group subscriptions for your colleagues and teams, please contact Teresa Hall at thall[at]africacapitaldigest.com today.